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Abstract
Background: Dried blood spots (DBS) are used in human medicine to measure 
total 25-hydroxyvitamin D (25-OHD) in the blood. However, this easy and afford-
able sampling technique has not been evaluated in primates to measure vitamin D 
concentrations.
Objectives: We aimed to compare 25-OHD measurements in chimpanzee serum 
at two different laboratories and determine the precision and accuracy of the DBS 
method by comparing DBS and serum results.
Methods: Blood samples from 17 captive chimpanzees were collected, and 25-OHD3 
and 25-OHD2 were measured in serum at two accredited laboratories using liquid 
chromatography-tandem mass spectrometry. The same analytes were measured on 
DBS cards, and results were compared with that of  serum. Data were assessed using 
the Spearman correlation, Deming regression, and Bland-Altman analyses.
Results: The correlation coefficient between the two measurements in serum was 
rs = .51 (P = .04), and the mean bias was −1.25 ± 14.83. When comparing 25-OHD 
concentrations measured in DBS and serum at the same laboratory, the rs was 0.7 
(P = .002), and the mean bias was 1.42 ± 14.58. Estimated intra-assay and inter-assay 
coefficients of variation for DBS results were 6% and 12.6%, respectively.
Conclusions: Although substantial analytical variability was found in 25-OHD 
measurements regardless of the sample type, the identification of both constant 
and proportional error and wider limits of agreement with the DBS technique 
makes the interpretation of DBS results challenging, especially for values close to 
clinical cut-off points. The DBS and serum methods were not interchangeable, and 
further studies are needed to validate DBS samples for vitamin D measurements 
in chimpanzees.
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1  | INTRODUC TION
Vitamin D is a fat-soluble vitamin that includes vitamin D3, produced 
in the skin from sun exposure, and vitamin D2, which is obtained from 
food. In humans and other primates, the predominant circulating form 
of vitamin D is 25-hydroxyvitamin D (25-OHD), comprising 25-OHD2 
and 25-OHD3. Although the major function of vitamin D is to maintain 
adequate serum calcium and phosphorus concentrations in blood, it has 
a wide range of other biologic actions.1 Low vitamin D concentrations 
in people have been associated with both an increased risk of mortality 
and a variety of disorders, including musculoskeletal diseases, diabetes 
mellitus, cardiovascular diseases, autoimmune diseases, and cancer.2,3
Few studies have assessed vitamin D concentrations in non-hu-
man primates4,5; however, vitamin D deficiency has been diagnosed 
in juvenile chimpanzees with rickets,6 and one study suggested that 
adult captive chimpanzees experienced vitamin D deficiency when 
housed without regular access to unfiltered sunlight.5 Another study 
measuring nutritional parameters in nine species of captive primates 
found that most of them had serum 25-OHD levels below published 
levels for humans and other primates and that chimpanzees had the 
lowest serum levels.4 However, since none of these animals showed 
clinical signs of vitamin D deficiency, the significance of the findings 
is uncertain, and the question of normal serum vitamin D values in 
chimpanzees remains unanswered. To establish RIs for this taxon, 
ideally, concentrations should be measured in healthy individuals 
living in their natural geographical ranges with unlimited sun expo-
sure. This represents a challenge because of limited access to sam-
ples from these populations and little availability of micronutrient 
analysis in situ.
Precision and reliability of 25-OHD measurements in serum vary 
depending on the laboratory, analytical technique, and other factors 
such as equipment calibration and maintenance.7 The Vitamin D 
External Quality Assessment Scheme (DEQAS) is the largest special-
ized external quality assessment scheme for vitamin D metabolites 
and assessed and monitors the accuracy of results produced by its 
certified laboratories where 75% of the results have to be within 
±25% of a target value.8 At present, it is accepted that liquid chro-
matography-tandem mass spectrometry (LC-MS/MS) offers the best 
accuracy for vitamin D metabolite measurements and is considered 
the gold-standard technique.9 However, the DEQAS 2016/2017 re-
view reported that in April 2017, the mean bias of LC-MS/MS as-
says (against target values assigned by the US National Institute of 
Standards and Technology) among DEQAS accredited laboratories 
was 9.3%, which was over the Vitamin D Standardization Program 
(VDSP) acceptable bias of 5%, and a mean CV of 9.4% (just below the 
VDSP threshold of 10%).10-12
Although serum or plasma samples are the standard biologic 
specimens used for measuring 25-OHD concentrations in human 
medicine, it has been shown that 25-OHD concentration measure-
ments in dried blood spots (DBS) are accurate and precise.13 The DBS 
technique uses drops of capillary blood collected on filter paper and 
is minimally invasive and of low-cost, requiring limited sample pro-
cessing that can be easily applied to field-based research settings. 
One of the significant advantages of DBS samples is that they do not 
need to be centrifuged, separated, or frozen following collection. In 
veterinary medicine, the DBS method has been used for the detec-
tion of toxins in mammals and birds,14,15 pharmacokinetic studies in 
rats and mice,16 and avian sexing with PCR.17 However, this tech-
nique has not been validated for any testing in primates.
The objective of this study was to measure 25-OHD (25-
OHD3 + 25-OHD2) in captive chimpanzee DBSs and calculate the 
intra- and inter-assay precision and accuracy compared with the 
measurements in serum. Measurements in serum at two different 
laboratories were also compared. This project aimed to contribute to 
the field of zoological medicine by evaluating an easy and affordable 
sampling technique to measure an important metabolic variable in 
great apes.
2  | MATERIAL AND METHODS
2.1 | Sample collection
This project has received the approval of the ethical review com-
mittee of the University of Nottingham's School of Veterinary 
Medicine and Science. Routine health-checks were carried out 
between April and September 2018 on seven male and 10 female 
chimpanzees (Pan troglodytes) held at Twycross Zoo, UK, and that 
needed to be transferred into a new enclosure. Ages ranged from 11 
to 54 years. Premedication consisted of 0.5mg/kg midazolam orally 
30 minutes before anesthesia was induced with an intramuscular 
injection of medetomidine (0.02 mg/kg) and tiletamine-zolazepam 
(2 mg/kg). Anesthesia was maintained with inhaled isoflurane in 
oxygen. Respiratory rate, heart rate, body temperature, invasive, 
and non-invasive blood pressure, end-tidal CO2, oxygen saturation, 
and end-tidal isoflurane were monitored continuously. A complete 
health-check was performed on each animal, including a full physical 
examination, hematology and biochemistry panels, abdominal and 
cardiac ultrasound, dental examination, urinalysis, and tuberculosis 
skin testing. Following standard operating procedures for great ape 
routine health-checks, 60 mL of venous blood was collected from 
the femoral vein of all animals for analysis and storage. Three indi-
vidual DBS cards were prepared for each animal by applying four 
drops of whole blood directly from the syringe (after removing the 
needle) onto each card. The cards were provided by the Sandwell 
and West Birmingham NHS Hospital Clinical Biochemistry depart-
ment (Whatman 903; GE Healthcare). Considering that each drop 
of blood collected on the paper card had an estimated volume of 
50 µL, it was calculated that approximately 200 µL of whole blood 
was needed for each DBS card.
2.2 | Sample processing
For serum preparation, whole blood samples were allowed to clot 
at room temperature for 1-3 hours and then centrifuged (1000g for 
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10 minutes). Serum was separated using a Pasteur pipette and ap-
portioned into 0.5-1.5 mL aliquots. Two 0.5 mL serum aliquots were 
stored at 7°C overnight and sent to different external laboratories 
the following day: the Sandwell and West Birmingham NHS Hospital 
Clinical Biochemistry department (“Laboratory A”) and Laboratory 
Medicine-Central Manchester University Hospitals (“Laboratory B”).
At Laboratory B, samples were prepared for analysis by add-
ing 150 µL of an Internal Standard (IS) solution (25-OHD2-d3 and 
25-OHD3-d6) in acetonitrile to 75 µL of serum, vortex mixed for 
5 minutes, and centrifuged for 4 minutes. Thirty microliters of the 
resultant supernatant were injected into a Transcend II liquid chro-
matography sample preparation system using TurboFlow online 
sample preparation technology (Thermo Fisher Scientific). After 
automated online sample preparation (TurboFlow C8 XL column 
[0.5 × 50 mm]), the analytes were separated by the analytical column 
(Accucore C8, [2.6 µm, 2.1 × 50 mm], Thermo Fisher Scientific) main-
tained at 60°C. The aqueous mobile phase was 10 mmol/L ammo-
nium acetate with 0.1% formic acid in water, and the organic mobile 
phase (OMP) was 10 mmol/L ammonium acetate with 0.1% formic 
acid in methanol. Chromatographic separation was achieved with a 
gradient program of 0-2.33 minutes at 15% OMP; 2.33-3.08 min-
utes at 80% OMP; 3.08-3.83 minutes with a linear gradient of OMP 
from 80% to 90%; 3.83-4.83 minutes at 100% OMP; returning to 
15% OMP for 4.83-5.83 minutes to re-equilibrate the column. The 
flow rate was 0.6 mL/min. Mass spectrometric detection was per-
formed using a TSQ Endura tandem quadrupole mass spectrometer 
(Thermo Fisher Scientific) with atmospheric pressure chemical ion-
ization in positive mode at 400°C. Analyte quantification was de-
termined against Chromsystems Multi-Level Serum 25-OH-Vitamin 
D3/D2 calibrators (Chromsystems) using TraceFinder (version 3.2) 
software (Thermo Fisher Scientific). Reported coefficients of re-
peatability for 25-OHD3 measurements in human sera were 4.6% at 
29.3 nmol/L, and 3.7% at 85.8 nmol/L. Dynamic ranges (quantitative 
reporting ranges) for the assay were 5-128 nmol/L for 25-OHD2 and 
5-173 nmol/L for 25-OHD3.
At Laboratory A, liquid-liquid extractions were performed 
by adding 150 µL of sample, calibrator, or control to 25 µL of the 
IS solution, and then to 150 µL of a 0.2 mol/L zinc sulfate solution, 
300 µL of methanol, and 700 µL of hexane; the mixture was then 
vortexed and centrifuged. The hexane layer was transferred to a 
96-well plate and left to evaporate to dryness, then each well was 
re-constituted with 80 µL of a 70% methanol:water loading solvent 
and 20 µL of sample injected onto an Acquity ultraperformance liq-
uid chromatography (UPLC) BEH Phenyl 1.7 μm, 2.1 mm × 50 mm 
column (Waters Inc.) at a temperature of 35°C.
Chromatographic separation was performed with a similar gradi-
ent at Laboratory B with a run time of 4.5 mins at 0.45 mL/min, using 
electrospray ionization source in positive ion mode. Mass spectro-
metric detection was performed using a Xevo triple quadrupole 
(TQD) mass spectrometer (Waters) with a qualifier transition as an 
added assurance. Chromsystem Multi-Level Serum 25-OH-Vitamin 
D3/D2 calibrators and Targetlynx data processing software (Waters) 
were used for quantification. Reported intermediate precisions for 
25-OHD3 measurements in human sera were 7.1% at 27.9 nmol/L 
and 4.8% at 97.8 nmol/L. Dynamic ranges for this assay were 2.8-
450 nmol/L for 25-OHD2 and 7.5-450 nmol/L for 25-OHD3.
Both laboratories are accredited by the United Kingdom 
Accreditation Service, hold an ISO-15189:2012 certification, and 
participate in DEQAS external quality assurance.8
The DBS cards were allowed to dry for 2 hours at room tem-
perature, then placed into hermetically sealed plastic bags contain-
ing silica gel and stored at room temperature. Two of the cards for 
each animal (DBS1 and DBS2) were sent to Laboratory A the day 
after collection and analyzed within the same batch, and the third 
card (DBS3) was sent to the same laboratory 1-2 weeks after col-
lection to be analyzed in a different batch. Samples were analyzed 
using LC-MS/MS on a Waters Acquity UPLC and Waters TQD Mass 
Spectrometer, following liquid-liquid extraction, as previously de-
scribed.18 This human assay has been standardized against human 
conventional serum and plasma 25-OHD3 and D2 LC-MS/MS (Waters 
TQD MS and Acquity UPLC) using specific blood calibrators (with a 
standard hematocrit of 45%); hence, blood spot results in people are 
equivalent to the serum/plasma concentrations if a collected venous 
sample, without requiring a conversion factor. For the preparation of 
calibration and quality control samples, raw 25-OHD concentrations 
in DBS were corrected for the hematocrit fractions using the follow-
ing formula (values in nmol/L) 18: Plasma25OHD = DBS25OHD/(1 − the 
hematocrit fraction). The laboratory-derived intra-assay variation 
for 25-OHD on human DBS cards is <10% and inter-assay variation 
was <15%. All DBS samples were analyzed in duplicate by the labo-
ratory, taking a central 3 mm punch from each of the two best blood 
spots and reporting the results as the average of the two. Dynamic 
ranges of the DBS assay were 2.8-450 nmol/L for 25-OHD2 and 7.5-
450 nmol/L for 25-OHD3.
2.3 | Data analysis
As the 25-OHD2 concentrations were reported to be less than 
5 nmol/L in all samples analyzed at Laboratory B and equal to 
2.8 nmol/L in all samples analyzed at Laboratory A, only the 25-
OHD (vitamin D total) results were included. The mean results for 
DBS1 and DBS2 pairs were calculated and thereafter called DBS12.
Results were analyzed using GraphPad Prism software (version 
8.0.2, La Jolla, CA). The Shapiro-Wilk test was used to test 25-OHD 
concentrations and calculate the differences (serum lab B-serum lab 
A, DBS12-serum lab A, DBS3-DBS12) for normality (α = 0.05).
Results from serum at Laboratories A and B were analyzed using 
a non-parametric Spearman correlation and Deming regression, and 
agreement was evaluated with a Bland-Altman analysis of the dif-
ferences.19 Standard deviations used for Deming regressions were 
estimated from the reported intra-assay variations using the formula 
SD = CV/100 × mean. One-sample t tests were performed on calcu-
lated differences (Lab A − Lab B), and linear regression of the differ-
ences was plotted on the Bland-Altman graph to detect proportional 
bias. Outliers were not removed.
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The coefficients of variation and SD for the DBS were cal-
culated using the formulas for the CV and SD based on duplicate 
samples.20,21
Laboratory A (serum Lab A) was considered the reference 
method, as their DBS technique has been calibrated against a con-
ventional LC-MS/MS on serum. Results from DBS12 and serum 
Laboratory A were compared and analyzed with the same statisti-
cal methods used for the comparison between Laboratories A and 
B, and acceptability of the DBS method was judged by calculating 
the percentage of DBS12 results that fall within ±25% of serum 
Laboratory A results, as this corresponds to DEQAS performance 
target and has been suggested as the acceptable performance for 
25-OHD measurements.22-24
Differences between DBS12 and DBS3 results were calculated 
and analyzed with a one-sample t test. Differences expressed in the 
percentage of DBS12 were calculated and plotted against DBS12.
Finally, the absolute differences between the hematocrit results 
and a standard hematocrit of 45% were calculated, tested for nor-
mality with the Shapiro-Wilk test, and compared with the absolute 
differences between DBS12 and lab A using a Pearson correlation.
3  | RESULTS
Total 25-OHD concentrations measured in serum and DBS, calcu-
lated differences, and hematocrit results, are shown in Table 1.
25-OHD concentrations in serum at Laboratories A and B were 
not normally distributed, and the Spearman correlation coefficient, 
rs, was .5 (95% CI = 0.02-0.8; P = .04). Estimated SD at a mean 25-
OHD concentration of 82 nmol/L were 3.93 for Laboratory A and 
3.00 for Laboratory B. These SD were used to compute a Deming 
regression, which values were: slope 1.46 (95% CI = 0.66-2.25); Y-
intercept −35.82 (95% CI = −98.03 to 26.40). Differences between 
results at the two laboratories were normally distributed. The 
Bland-Altman analysis revealed a mean bias of −1.25 (SD = 14.83) 
that did not differ significantly from 0 on a one-sample t test 
(t = 0.347, df = 16, P = .733). On the Bland-Altman plot, magnitudes 
of the differences did not seem to increase at lower or higher con-
centrations of 25-OHD: linear regression line slope was −0.28 (95% 
CI= −0.65 to 0.1), not significantly different from 0 (P = .14). The 95% 
limits of agreements were −30.31 to 27.61. Chimp 15 was identified 
as an outlier on the Bland-Altman plot with a bias of 36.60 (Figure 1).
The CV for the DBS1 and DBS2 pairs was 6%, and the CV com-
puted between the mean of DBS1 and DBS2 with DBS3 was 12.6%. 
The calculated SD for the DBS12 pairs was 5.55.
The mean results of the pairs, DBS1 and DBS2 (thereafter called 
DBS12), were not normally distributed. The Spearman correla-
tion computed between DBS12 and Laboratory A results yielded 
a correlation coefficient of 0.7 (95% CI = 0.31-0.89; P = .024). 
Values for the Deming regression analysis (using SD = 3.93 for lab 
A, and SD = 5.55 for DBS12) were slope 1.86 (95% CI = 1.17-2.55); 
Y-intercept −71.41 (95% CI = −125.8 to −17.05). Differences in 25-
OHD concentrations between DBS12 and Laboratory A were nor-
mally distributed. The Bland-Altman analysis revealed a mean bias 
of −1.42 (SD = 19.58) that was not significantly different from 0 on 
a one-sample t test (t = 0.299, df = 16; P = .769). 95% limits of agree-
ments were −39.80 to 36.96, with chimpanzee 13 identified as an 
outlier with a bias of −41.75 (Figure 2). Linear regression analysis 
of the differences identified a significant positive proportional bias 
(slope = 0.6; 95% CI = 0.34-0.87; P = .0002) and a negative con-
stant bias (Y-intercept = −50.30; 95% CI= −72.70 to −27.89), which 
resulted in an average negative bias at results less than 83.15 nmo-
l/L (X-intercept) but with a positive bias above this concentration 
(Figure 2). Only 9/17 (53%) of the DBS12 results were within ±25% 
of Laboratory A results (Figure 3).
When comparing results from DBS3 with DBS12, differences 
were normally distributed, and the mean difference was −9.47 
(SD = 13.22, 95% CI = −16.27 to −2.68), which differed significantly 
F I G U R E  1   Spearman correlation and Bland-Altman analysis assessing agreement between total 25-hydroxyvitamin D measurements in 
serum at Laboratory A and Laboratory B. Blue continuous line: Deming regression line. Blue dashed line: mean bias. Gray continuous line: 
linear regression line. Black dotted lines: 95% limits of agreement (±1.96 SD). The identify line (Y = X) is also provided on the correlation 
graph
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from 0 on a one-sample t test (t = 2.96, df = 16; P = .009), showing 
that the 25-OHD concentration on the DBS3 card was generally 
lower than on the DBS1 and DBS2 cards. When expressed on a per-
centage of the DBS12 cards, the differences were between −31.47% 
and 14.92% (mean difference −8.39% ± 14.21) (Figure 4).
The calculated absolute differences between the hematocrit re-
sults and a standard hematocrit of 45% were normally distributed. 
A Spearman correlation between these differences and the absolute 
differences between DBS12 and lab A was not significant (α = 0.05) 
with an r = .11 (95% CI = −0.40 to 0.57; P = .67).
4  | DISCUSSION
The correlation between 25-OHD measurements on chimpanzee 
DBS cards and serum could be considered strong using traditional 
approaches of interpreting correlation coefficients.25 However, lim-
its of agreements were wide, and both constant and proportional 
errors were identified using the DBS method when compared with 
measurements in serum at the reference laboratory. Only 53% of 
DBS card results showed an error within acceptance limits used in 
people. The correlation was moderate between the measurements 
in serum at the two different laboratories; however, no significant 
constant nor proportional error was identified.
Liquid chromatography-tandem mass spectrometry is currently 
established as the gold standard for the measurement of vitamin-D 
compounds due to improved analytical specificity and sensitivity, 
and a wider dynamic range compared with immunoassay meth-
ods.9 It is widely recognized that there are substantial differences in 
human serum 25-OHD measurements not only between assays but 
also between laboratories using LC-MS/MS.7 Due to this analytical 
variability and pre-analytical factors for serum 25-OHD variation 
(season, sun exposure, and skin type), no evidence-based interna-
tional consensus on a human vitamin D RI exists.26 It is, however, 
recognized that 25-OHD concentrations below 30 nmol/L increase 
the risk of poor musculoskeletal health, while concentrations be-
tween 50-125 nmol/L appear to be safe and sufficient.27-29 Cases 
of vitamin D toxicity are rare and associated with serum 25-OHD 
concentrations above 300 nmol/L.28
The presented comparison between 25-OHD measurements 
in chimpanzee serum at two accredited laboratories allows con-
textualizing the variation found between serum and the DBS tech-
nique. A maximum bias of 36.60 nmol/L and limits of agreements 
as wide as −30.31 to 27.81 between chimpanzee serum samples 
stresses the fact that results of vitamin D levels in chimpanzees 
must be interpreted with care regardless of the sample type, es-
pecially for values close to human published cut-off points. For 
this study, serum samples were sent at ambient temperature as it 
has been shown that 25(OH)-vitamin D3 in its natural state bound 
to vitamin D-binding protein is very stable at room temperature, 
F I G U R E  2   Spearman correlation and Bland-Altman analysis assessing agreement between total 25-hydroxyvitamin D measurements 
in serum at Laboratory A and dried blood spots of the DBS1 and DBS2 pairs (DBS12). Blue continuous line: Deming regression line. Blue 
dashed line: mean bias. Gray continuous line: linear regression line. Black dotted lines: 95% limits of agreement (±1.96 SD). The identify line 
(Y = X) is also provided on the correlation graph
F I G U R E  3   Differences between total 25-hydroxyvitamin 
D measurements in dried blood spots of the DBS1 and DBS2 
pairs (DBS12) and serum at Laboratory A showing the ± 25% 
acceptability lines (black dashed lines)
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and decreases noted after 3 days at around 20°C under com-
mon pre-analytical conditions are less than analytical inter-assay 
precision.30
Dried blood spots matrix-matched calibrators used by Laboratory 
A are produced with a human hematocrit of 45%. As most 25-OHD is 
present in serum and not in red blood cells, extreme hematocrit val-
ues in the analyzed samples could lower the accuracy of the 25OHD 
results on DBS cards compared with that of serum. The chimpan-
zees in this study had a wide range of hematocrit levels, ranging 
from 24.1% to 60%. Interestingly, chimpanzee 13, who had the low-
est value of hematocrit, was an outlier in the Bland-Altman analy-
sis comparing serum and DBS results. Although statistical analysis 
failed to reveal a correlation between the differences in hematocrits 
(compared with a standard 45%), and differences in vitamin D lev-
els between assays, veterinarians should be aware that vitamin D 
concentrations measured on DBS cards could be falsely increased in 
animals with very low hematocrits and falsely decreased in animals 
with very high hematocrits.
The CV of 6% calculated between the DBS1 and DBS2 pairs 
encompass both the within-batch analytical CV of the assay for 
chimpanzees (intra-assay variation) and the variations due to the 
DBS quality (spot size, diffusion of blood). The result is comparable 
to the reported intra-assay CV for the human DBS assay of <10%, 
thus suggesting little variation due to DBS quality in this study. 
The CV of 12.6% calculated between mean DBS12 and DBS3 ad-
ditionally incorporates batch assay variation and the stability of 
vitamin 25-OHD in the DBSs. This result is also comparable to 
the inter-assay CV of <15% reported by Laboratory A for human 
DBS. The fact that the third blood spot card, analyzed at a later 
time point, showed generally lower values than the first two DBSs 
could put into question the stability of vitamin 25-OHD in a chim-
panzee's DBS. However, in unprocessed whole blood, vitamin D 
metabolites are considered very stable,30 and a study found no 
significant effect of different storage condition (at −20°C, 2 weeks 
in the dark at room temperature, and 2 weeks in full light and open 
box at room temperature) on vitamin D levels in DBSs.18 All the 
DBS cards in this current study were stored in sealed plastic bags 
with desiccant gel in the dark, to minimize analyte degradation. 
The difference between the third DBS and the other DBSs could 
thus be attributable to inter-assay variation only, or to the limited 
number of samples.
The blood sample used to prepare the DBS in this study was 
from one single venous blood sample to avoid multiple sampling. 
DBS cards are designed and calibrated for using capillary blood; 
however, excellent agreement was found between venous and 
capillary serum 25OHD concentrations measured by LC/MS-MS in 
people.31 A known source of inaccuracy and variation in DBS results 
come from the quality of the blood spots on the Whitman paper. 
In a field setting, creating well-sized and homogeneous blood spots 
is challenging. The laboratory used in this study tried to overcome 
this problem by performing duplicate measurements using a central 
3 mm punch from two of the best spots on the card and providing 
the mean concentration.
Important study limitations were the relatively low number of 
samples included and the fact that most of the measured 25-OHD 
concentrations were in the middle to high part of the analytical 
range and did not cover the whole working range of the method. 
This does not adhere to recommendations for method comparison 
experiments32; however, adequate sample numbers and ranges are 
challenging to achieve when working with zoo species that can only 
be sampled opportunistically during health-checks or translocations.
Recommendations to calculate the total allowable analytical 
error for new laboratory methods32 are difficult to apply in this cur-
rent study because the inherent imprecisions of the methods used 
are unknown for chimpanzees, and acceptance limits, based on ana-
lytical quality specifications, can only be estimated following recom-
mendations from people. However, as the imprecision estimated for 
the DBS technique in chimpanzees was similar to the reported im-
precisions for human serum and DBSs, the use of acceptance limits 
based on External Quality Assessment scheme for human 25-OHD 
seems reasonable. 25-OHD concentrations in serum at Laboratory A 
were considered as references when estimating the DBS technique 
acceptability. The fact that only 9/17 of the DBS12 results were 
within ±25% of laboratory serum results categorizes the DBS tech-
nique in chimpanzees as unacceptable according to human quality 
schemes. However, an important limitation of our study is that the 
true total-25OHD concentration is unknown; thus, the accuracy of 
the DBS method in chimpanzees can only be estimated. To validate 
the DBS method for vitamin D measurements in chimpanzees, fur-
ther within-laboratory experiments for this sample type are needed, 
including accuracy measurements against a “true” value, recovery, 
and interference studies, additional tests on imprecision, and the 
creation of specific RIs.33
Until further validation studies are carried out, zoo and wildlife 
veterinarians should only use DBS samples to estimate vitamin D 
status in chimpanzees when serum collection and/or storage is not 
possible, and avoid making clinical diagnostics based on 25-OHD re-
sults from DBS, as the analytical error of this method might not allow 
discriminating between normal and abnormal values.
F I G U R E  4   Percentage of difference between DBS3 and the 
DBS1 and DBS2 pairs (DBS12), plotted against DBS12. Blue dashed 
line: mean % difference. Black dotted lines: 95% confidence interval
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